Dec 2020; The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group in desperate need of new and effective treatments.
Inventiones hae praesentatae sunt in Societate Hematologiae Americanae virtualem 2020 Annuum Conventum.
Traditionally, around half of patients with high-risk LBCL, a subgroup of the disease in which patients have double- or triple-hit lymphoma or additional clinical risk factors identified by the International Prognostic Index (IPI), have not achieved long-term disease remission with standard treatment approaches such as chemoimmunotherapy.
This trial represents a step toward making CAR T Lorem cellulam a first-line treatment option for patients with aggressive B-cell lymphoma,” said Sattva S. Neelapu, M.D., professor of Lymphoma and Myeloma. “At the moment, patients with newly diagnosed aggressive B-cell lymphoma get chemotherapy for about six months. CAR T Lorem cellulam, if successful, may make it a one-time infusion with treatment completed in one month.
Ex clavibus investigationis ZUMA-1, Axi-cel nunc licentiatus est pro curatione hominum relapsus vel refractorius LBCL qui iam duas vel plures lineas curationum systemicarum iam habuit. ZUMA-12 probatio est Phase 2 apertus titulus, simplex bracchium, multicenter iudicium quod super inventiones ZUMA-1 aedificat, ad usum axi-cel perpendendi sicut primi lineae therapiae pro aegris magno periculo LBCL .
Secundum ZUMA-12 interim studium, 85 centesimas aegrorum cum axi-cel tractatas altiore responsione habuit, et 74% plenam responsionem habuit. Post mediana sectarum 9.3 mensium, 70% aegrorum conscriptorum responsionem continuam in notitia intervalli exhibebat.
White blood cell count reduction, encephalopathy, anaemia, and cytokine release syndrome were the most common side effects linked with axi-cel treatment. By the time the data was analysed, all adverse events had been resolved.
Furthermore, when compared to when the immunotherapy products were generated from patients who had already received several lines of chemotherapy, the peak level of CAR T cells present in the blood, as well as the median CAR T cell expansion, were higher in this trial of first-line CAR T Lorem cellulam.
"Haec T cellae congruentia cum maiore efficacia medicinali coniungi potuit, ex melioribus eventibus patientibus" Neelapu addidit.
Sequentes excellentes eventus interim ZUMA-12, investigatores instituunt ut aegros prosequantur, ut reactiones ad medicamen diuturnum sint.
“A randomised clinical trial would be required to definitely demonstrate that CAR T cell therapy is superior to existing standard of care with chemoimmunotherapy in these high-risk patients if the responses are persistent after prolonged follow-up,” Neelapu said. It also begs the question of whether CAR T cell treatment should be tested in intermediate-risk patients with big B-cell lymphoma.
